A new class of conditionally active biologics that is safer and less toxic than existing therapies is emerging. These drugs have the potential to overcome shortcomings of current state-of-the-art therapies, including but not limited to ADCs and bispecifics. Companies in this field are currently focused on oncology and immunology, but many of their technologies can be applied to any protein therapeutic where regulation is required to achieve a sufficient therapeutic index (e.g in fibrosis, a collagen-regulated TFGb antagonist, or, in diabetes, a glucose-regulated insulin). Attendees will walk away from this session with three key takeaways: conditionally active biologics represent a new class of safer and more efficacious treatments that will directly benefit patients with devastating diseases; conditionally active drugs regulate their own activity, making them inactive in circulation and enabling them to switch to an active conformation when bound to a specific marker; and lastly, this field represents a significant emerging opportunity for biotech and pharma.